[China coronary secondary prevention study (CCSPS): outcomes from analysis of coronary heart disease patients with diabetes].
OBJECTIVE
To elucidate whether lipid-lowering therapy with Xuezhikang can induce a decrease of cardiac events and an attenuation of total mortality in coronary heart disease (CHD) patients with diabetes.


METHODS
We designed a random, double-blinded, placebo controlled clinical trial in selected 591 patients. All patients were administrated with capsule Xuezhikang (0.6 g, Bid) or placebo in addition to conventional therapy. The mean follow-up period was four years. The primary end-points were nonfatal myocardial infarction and death from CHD.


RESULTS
(1) The incidence of CHD events and that of death from CHD were reduced by 50.8% (P = 0.0008) and by 44.1% (P = 0.0246) in treatment group, respectively; Also, the incidence of nonfatal myocardial infarction was reduced by 63.8% (P = 0.0151). (2) The incidence of stroke, tumor, and PCI/CABG were decreased by 20.2%. (3) The total mortality were lowered by 44.1% in treatment group (P = 0.0097).


CONCLUSIONS
Xuezhikang can effectively reduce the incidence of cardiac events and total mortality in CHD patients with diabetes.
Cardiovascular Institute and Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.
Zong-liang
ZL
Lu
Bao-min
BM
Du
Zuo
Z
Chen
Yang-feng
YF
Wu
Xue-hai
XH
Yu
Yu-chen
YC
Zhao
D000368:Aged; D002681:China; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control*; D003920:Diabetes Mellitus; D004311:Double-Blind Method; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D055502:Secondary Prevention
D004365:Drugs, Chinese Herbal; D000960:Hypolipidemic Agents; C496822:xuezhikang